Anzeige
Mehr »
Login
Donnerstag, 24.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QHYP | ISIN: US89422G1076 | Ticker-Symbol: 17R
Berlin
24.04.25
15:39 Uhr
14,800 Euro
+0,200
+1,37 %
1-Jahres-Chart
TRAVERE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
TRAVERE THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
15,40015,50016:22

Aktuelle News zur TRAVERE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
10.04.Canaccord raises Travere stock target to $47, maintains Buy rating6
03.04.Novartis Pops - Hammering Rival Travere Therapeutics - On Its Kidney Drug Approval14
TRAVERE THERAPEUTICS Aktie jetzt für 0€ handeln
03.04.Cantor Fitzgerald stays bullish on Travere Therapeutics stock2
01.04.The Analyst Verdict: Travere Therapeutics In The Eyes Of 7 Experts2
28.03.IBD Stock Of The Day Travere Therapeutics: A Breakout And $1 Billion Opportunity Loom2
17.03.Travere Therapeutics, Inc. - 8-K, Current Report-
17.03.Travere Therapeutics, Inc.: Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI (sparsentan) for the Treatment of FSGS156sNDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS If approved, FILSPARI could become the first and only FDA-approved treatment for FSGS, a rare kidney...
► Artikel lesen
12.03.Travere Therapeutics, Inc.: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)81SAN DIEGO, March 12, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on March 10, 2025, the Compensation Committee of its Board of Directors granted inducement...
► Artikel lesen
24.02.Analyst Expectations For Travere Therapeutics' Future5
23.02.Travere Therapeutics, Inc. (TVTX): the Best Performing Pharma Stock So Far in 20251
21.02.After asset purchase from Travere, Mirum's Ctexli crosses FDA finish line in rare metabolic disorder1
21.02.Travere Therapeutics, Inc. - 10-K, Annual Report-
20.02.Travere Therapeutics, Inc.: Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results133Company to submit sNDA around the end of 1Q 2025 seeking traditional approval of FILSPARI® (sparsentan) for FSGS Net product sales of FILSPARI totaled $50 million in 4Q 2024; $132 million for full...
► Artikel lesen
20.02.Travere Therapeutics, Inc. - 8-K, Current Report1
13.02.Travere Therapeutics, Inc.: Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results2
12.02.Travere Therapeutics, Inc.: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)74SAN DIEGO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on February 10, 2025, the Compensation Committee of its Board of Directors granted inducement...
► Artikel lesen
12.02.Why Travere Therapeutics Inc. (TVTX) Went Up On Tuesday?1
12.02.Scotiabank raises Travere stock target to $32 on FDA update5
12.02.Canaccord raises Travere Therapeutics target to $45; Keeps Buy1
12.02.Travere takes rare disease kidney drug to FDA despite failed trial2
Seite:  Weiter >>
55 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1